Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | LDHA | P00338 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | AGXT | P21549 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2265778 | 1.00 | SLC6A4 (0.61) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL7294911 | 1.00 | SLC6A4 (0.61) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL9630894 | 0.82 | NQO1 (0.48) | ACACB | |
| SCHEMBL9499665 | 0.82 | NQO1 (0.48) | ACACB | |
| SCHEMBL9630902 | 0.82 | NQO1 (0.48) | ACACB | |
| SCHEMBL26922534 | 0.81 | SLC6A4 (0.61) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL8693993 | 0.81 | LDHA (0.56) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL10384433 | 0.81 | ACACB (0.47) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL7020048 | 0.81 | ACACB (0.47) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL7020330 | 0.81 | ACACB (0.47) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | claimed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | claimed |
| EP-0767794-B1 | PHOSPHINIC ACID DERIVATIVES | SCHERING CORP (US) | 2000-02-02 | — | — | EP | claimed |
| US-5140009-A | Stable against proteolytic enzymes; anticarcinogenic agents; urogenital disorders | TAP PHARMACEUTICALS, INC. (US) | 1992-08-18 | — | — | US | claimed |
| EP-0480918-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1992-04-22 | — | — | EP | claimed |
| EP-0480918-A4 | REDUCED SIZE LHRH ANALOGS. | ABBOTT LAB (US) | 1991-06-04 | — | — | EP | claimed |
| EP-0417454-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1991-03-20 | — | — | EP | claimed |
| EP-0400065-A4 | LHRH ANALOGS | — | 1991-03-13 | — | — | EP | claimed |
| EP-0413209-A1 | LHRH analogs | TAP Pharmaceuticals Inc. (US) | 1991-02-20 | — | — | EP | claimed |
| EP-0400065-A1 | LHRH ANALOGS. | ABBOTT LAB (US) | 1990-12-05 | — | — | EP | claimed |
| US-4818748-A | HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-04-04 | — | — | US | claimed |
| WO-1988005049-A1 | NOVEL COMPOUNDS | Aktiebolaget Hässle (SE) | 1988-07-14 | — | — | WO | claimed |
| EP-0273893-A2 | Novel compounds | Aktiebolaget Hässle (SE) | 1988-07-06 | — | — | EP | claimed |
| EP-0127899-B1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | The Administrators of The Tulane University Educational Fund (US) | 1987-10-21 | — | — | EP | claimed |
| EP-0236874-A2 | Renin inhibitors, their production and use, as well as derivatives of amino acids and amino aldehydes | BAYER AG (DE) | 1987-09-16 | — | — | EP | claimed |
| EP-0214570-A2 | N-alkylated tripeptides, process for their preparation, medicaments containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-03-18 | — | — | EP | claimed |
| EP-0188214-A2 | Novel growth hormone-releasing peptides and method of treating mammals therewith | The Administrators of The Tulane University Educational Fund (US) | 1986-07-23 | — | — | EP | claimed |
| EP-0145768-A1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | COY, David Howard (US) | 1985-06-26 | — | — | EP | claimed |
| WO-1984004916-A1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | COY DAVID HOWARD (US) | 1984-12-20 | — | — | WO | claimed |
| EP-0127899-A1 | Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith | The Administrators of The Tulane University Educational Fund (US) | 1984-12-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | GNRHR, GRIN1, GRIN3A | SLC6A4 1207/4885CYP1A2 3674/4885CYP2D6 4094/4885 |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | GNRHR, GRIN1, GRIN3A | SLC6A4 1207/4885CYP1A2 3674/4885CYP2D6 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.